Zynex Stock

Zynex Equity

Delisted·Dec 23, 2025

The The Equity of Zynex (ZYXI) as of Aug 25, 2026 is 35.71 M USD. In the previous year, The Equity was 46.13 M USD — a change of -22.59% (lower).

Equity

35.71 MUSD

YoY

-22.59%

Last updated:

In 2026, Zynex's equity was 35.71 M USD, a -22.59% increase from the 46.13 M USD equity in the previous year.

The Zynex Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
4.99 M USD
Jan 1, 2018
9.39 M USD
Jan 1, 2019
19.74 M USD
Jan 1, 2020
56.86 M USD
Jan 1, 2021
73.93 M USD
Jan 1, 2022
66.36 M USD
Jan 1, 2023
46.13 M USD
Jan 1, 2024
35.71 M USD
The Zynex Equity history
YEAREquityYoY
35.71 MUSD-22.59%
46.13 MUSD-30.48%
66.36 MUSD-10.24%
73.93 MUSD+30.02%
56.86 MUSD+187.99%
19.74 MUSD+110.31%
9.39 MUSD+88.08%
4.99 MUSD-234.42%
-3.71 MUSD-6.76%
-3.98 MUSD+231.56%
-1.20 MUSD
Access this data via the Eulerpool API

Zynex Stock analysis

What does Zynex do? Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market. The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility. Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement. Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously. Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain. Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions. An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment. Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe. Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Zynex's Equity

Zynex's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Zynex's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Zynex's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Zynex's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Zynex’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Zynex stock

The Equity of Zynex is 35.71 M USD in 2026.

The Equity of Zynex changed from 46.13 M USD to 35.71 M USD, representing a -22.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Zynex since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Zynex historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Zynex

All Key Metrics — Zynex